Title	Whole blood DNA methylation changes are associated with anti-TNI					
	drug concentration in patients with Crohn's disease					
Authors	Simeng Lin <sup>1,2</sup> *, Eilis Hannon <sup>3</sup> *, Mark Reppell <sup>4</sup> , Jeffrey F. Waring <sup>4</sup> , Nizar					
	Smaoui <sup>4</sup> , Valerie Pivorunas <sup>4</sup> , Heath Guay <sup>4</sup> , Neil Chanchlani <sup>1,2</sup> , Claire					
	Bewshea <sup>2</sup> , Benjamin Y H Bai <sup>5,6</sup> , Nicholas A Kennedy <sup>1,2</sup> , James R					
	Goodhand <sup>1,2</sup> , Jonathan Mill <sup>3</sup> *, Tariq Ahmad <sup>1,2</sup> *, PANTS Consortium					
	*denotes shared authorship					
Affiliations	<sup>1</sup> Gastroenterology, Royal Devon University Healthcare NHS Foundation					
	Trust, Exeter, UK					
	<sup>2</sup> Exeter Inflammatory Bowel Disease and Pharmacogenetics Research					
	Group, University of Exeter, Exeter, UK					
	<sup>3</sup> University of Exeter Medical School, Faculty of Health and Life Sciences,					
	University of Exeter, Exeter, UK					
	<sup>4</sup> AbbVie Inc., Chicago, IL, USA;					
	<sup>5</sup> Genomics of Inflammation and Immunity Group, Wellcome Sanger					
	Institute, Hinxton, UK;					
	<sup>6</sup> Postgraduate School of Life Sciences, University of Cambridge,					
	Cambridge, UK					
Address for	Tariq Ahmad, Exeter Inflammatory Bowel Disease and Pharmacogenetics					
correspondence	Research Group, RILD building, Barrack Road, Exeter. EX2 5DW, UK,					
	tariq.ahmad1@nhs.net					
Key words	DNA methylation, Epigenetics, Anti-TNF, Crohn's disease, IBD					
Running title	DNA methylation changes associated with anti-TNF drug concentration					
Word count	6,777					

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

#### Short title here

**Abstract Background and Aims** Anti-TNF treatment failure in patients with inflammatory bowel disease (IBD) is common and frequently related to low drug concentrations. In order to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy, we sought to define epigenetic biomarkers in whole blood at baseline associated with anti-TNF drug concentrations at week 14. Methods DNA methylation from 1,104 whole blood samples from the Personalised Anti-TNF Therapy in Crohn's disease (PANTS) study were assessed using the Illumina EPIC Beadchip at baseline, weeks 14, 30 and 54. We compared DNA methylation profiles in anti-TNF-treated patients who experienced primary non-response at week 14 and were not in remission at week 30 or 54 (infliximab n = 99, adalimumab n = 94) with patients who responded at week 14 and were in remission at week 30 or 54 (infliximab n = 99, adalimumab n = 93). Results Overall, between baseline and week 14, we observed 4,999 differentially methylated probes (DMPs)

# annotated to 2376 genes following anti-TNF treatment. Pathway analysis identified 108 significant gene ontology terms enriched in biological processes related to immune system processes and responses. Epigenome-wide association (EWAS) analysis identified 323 DMPs annotated to 210 genes at baseline associated with higher anti-TNF drug concentrations at week 14. Of these, 125 DMPs

#### Short title here

demonstrated shared associations with other common traits (proportion of shared CpGs compared to DMPs) including body mass index (23.2%), followed by CRP (11.5%), smoking (7.4%), alcohol consumption per day (7.1%) and IBD type (6.8%). EWAS of primary non-response to anti-TNF identified 20 DMPs that were associated with both anti-TNF drug concentration and primary non-response to anti-TNF with a strong correlation of the coefficients (Spearman's rho = -0.94, p < 0.001). 

Conclusion

Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy.

Introduction

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Anti-TNF therapies remain the most effective treatment to induce and maintain remission in patients with Crohn's disease<sup>1,2</sup>. Successful treatment leads to mucosal healing, reduced surgeries. and improvements in quality of life<sup>3</sup>. Unfortunately, anti-TNF treatment failure is common, with a quarter of patients experiencing primary non-response, and one-third of initial responders losing response by the end of the first year<sup>4</sup>. In the Personalised Anti-TNF Therapy in Crohn's Disease study (PANTS), whilst loss of response was associated with the formation of anti-drug antibodies that were predicted by carriage of the HLA-DQA1\*05 haplotype and mitigated by concomitant immunomodulator use, the only modifiable factor associated with primary non-response at week 14 was low anti-TNF drug concentration<sup>5,6</sup>. In this regard early dose optimisation reportedly improves anti-TNF response rates<sup>7,8</sup>. Whilst the biology of non-response is complex, an ability to predict primary non-response may inform treatment choice and identify individuals who may benefit from dose optimisation during induction therapy. Heterogeneity of response to anti-TNF therapies has led to a drive to understand the molecular mechanisms underlying treatment failure in anti-TNF therapy. Increased mucosal expression of oncostatin M (OSM)<sup>9,10</sup> and triggering receptor expressed on myeloid cells (TREM-1)<sup>11,12</sup> have been identified as potential biomarkers predicting non-response to anti-TNF treatment. Drawing conclusions across studies is difficult, however, due to differences in study design, improvements in experimental and computational methods through time and critically, confounding by cellular heterogeneity with contradictory results between whole blood and intestinal biopsies<sup>13</sup>. Clinical translation of tissue biomarkers has also further been limited by accessibility and processing costs<sup>14</sup>.

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

#### Short title here

DNA methylation, an epigenetic modification to DNA, can influence gene expression via disruption of transcription factor binding and recruitment of methyl-binding proteins that initiate chromatin compaction and gene silencing 15,16. Despite being traditionally regarded as a mechanism of transcriptional repression, DNA methylation is actually associated with both increased and decreased gene expression<sup>17</sup>, and other genomic functions including alternative splicing and promoter usage<sup>18</sup>. DNA methylation can be influenced by both genetic<sup>19</sup> and environmental factors<sup>20</sup>, changing with age<sup>21</sup> and exposures such as cigarette smoking<sup>22</sup>. The development of standardised assays for quantifying DNA methylation across the genome at single-base resolution in large numbers of samples has enabled researchers to perform epigenome-wide association studies (EWAS) aimed at identifying methylomic variation associated with exposures and traits<sup>23</sup>. EWAS analyses are inherently more complex to design and interpret than genetic association studies; the dynamic nature of epigenetic processes means that a range of potentially important confounding factors (including tissue or cell type, age, sex, and lifestyle exposures) need to be considered in between-group comparisons<sup>24</sup>. Previous studies of DNA methylation using whole blood or individual purified cell types have identified differentially methylated positions (DMPs) between patients with active and inactive IBD and healthy controls<sup>25,26</sup>. Pharmacoepigenomics is the application of epigenetics to understand interindividual differences in the response to therapeutic drugs<sup>27</sup>. DNA methylation sites from whole blood have been identified as effective biomarkers predicting treatment response to methotrexate and anti-TNF in patients with rheumatoid arthritis<sup>28,29</sup>. In this study we used a powerful intra-individual study design to identify changes in DNA methylation associated with anti-TNF drug treatment, profiling 385 patients at baseline and weeks 14, 30 and 54 post treatment initiation. In order to identify patients who may benefit from dose

4, 35 and 34 post treatment initiation. In order to identify patients who may belief thom dose

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

#### Short title here

optimisation at the outset of anti-TNF therapy, we also sought to define epigenetic biomarkers in whole blood at baseline associated with anti-TNF drug concentrations at week 14. We identify widespread differences in DNA methylation induced by anti-TNF drug treatment and show that baseline DNA methylation profiles can predict anti-TNF drug concentration at week 14. Methods Study design The PANTS study is a UK wide, multicentre, prospective observational cohort reporting the treatment failure rates of the anti-TNF drugs infliximab (originator, Remicade [Merck Sharp & Dohme, Hertfordshire, UK] and biosimilar, CTP13 [Celltrion, Incheon, South Korea]), and adalimumab (Humira [AbbVie, Cambridge, MA]) in 1610 anti-TNF-naïve patients with Crohn's disease. (Supplementary Table 1) Patients were recruited between February 2013 and June 2016 at the time of first anti-TNF exposure and studied for 12 months or until drug withdrawal. Eligible patients were aged ≥ 6 years with objective evidence of active luminal Crohn's disease involving the colon and/or small intestine. Exclusion criteria included prior exposure to, or contraindications for the use of, anti-TNF therapy. The choice of anti-TNF was at the discretion of the treating physician and prescribed according to the licensed dosing schedule. Study visits were scheduled at first dose, week 14, and at weeks 30 and 54. Additional visits were planned for infliximab-treated patients at each infusion and for both groups at treatment failure or exit. Treatment failure endpoints were primary non-response at week 14, non-remission at week 54, and adverse events leading to drug withdrawal.

We used composite endpoints using the Harvey Bradshaw Index (HBI) in adults and the short paediatric Crohn's disease activity index (sPCDAI) in children, corticosteroid use, and CRP to define primary non-response (Supplementary Figure 1). Remission was defined as CRP of ≤3 mg/L and HBI of ≤4 points (sPCDAI ≤15 in children), without corticosteroid therapy or exit for treatment failure. Variables recorded at baseline were patient demographics (age, sex, ethnicity, comorbidities, height and weight and smoking status) and IBD phenotype and its treatments (age at diagnosis, disease duration, Montreal classification, prior medical and drug history, and previous Crohn's diseaserelated surgeries). At every visit, disease activity score, weight, current therapy and adverse events were recorded. Blood and stool samples were collected at each visit and processed through the central laboratory at the Royal Devon & Exeter NHS Foundation Trust (https://www.exeterlaboratory.com/) for haemoglobin, white cell count, platelets, serum albumin, CRP, anti-TNF drug and anti-drug antibody concentrations, and faecal calprotectin, respectively. **DNA** methylation processing Genomic DNA was extracted from peripheral whole blood using the Qiagen Qiasymphony DNA DSP midi kit (Qiagen, Ca, USA). Following sodium bisulfite conversion with the Zymo Research EZ-DNA Methylation kit (Zymo Research, CA USA), DNA methylation was quantified across the genome using the Illumina Infinium HumanMethylationEPIC (EPIC) BeadChip (Illumina Inc, CA, USA). To negate any methodological batch effects, individuals were randomised across experimental batches and samples from the same individual were processed together across all experimental stages.

Data pre-processing and quality control checks

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Raw Illumina EPIC data were imported into R (version 3.6.0) using the bigmelon package (v1.12.0)<sup>30</sup>. Quality control (QC) checks were performed using the bigmelon (v1.12.0)<sup>30</sup> and minfi (v1.32.0)<sup>31</sup> R packages. They included the following steps: we first removed samples by 1) checking median methylated and unmethylated signal intensities and excluding samples with low intensities (<500) (3 samples excluded), 2) assessing bisulphite conversion efficacy of each sample and excluding samples with a conversion rate < 80% (9 samples excluded), 3) using the 59 single nucleotide polymorphism (SNP) probes present on the EPIC array to confirm all matched samples from the same individual were genetically identical and to check for sample switches or duplications (12 samples excluded), 4) comparing intensity values from probes located on the X and Y chromosomes to autosomes to identify sex mismatches (10 samples excluded), 5) visually inspecting the first six principal components and excluding outliers (none identified), 6) using the pfilter function in the bigmelon (v1.12.0) package to exclude samples where >1% of probes had a detection p-value >0.05 (none identified). We subsequently removed probes by 7) using the pfilter function in the bigmelon (v1.12.0) package to exclude probes with a bead count <3 or 1% of samples with a detection p-value > 0.05 (8313 probes) and 8) removal of cross-hybridising probes and those containing a SNP (73,239 probes). Following QC, quantile normalisation was carried out and 784,105 probes were taken forwards for analysis after exclusion of probes on the Y chromosome. Sample size and statistical methods Sample size calculations from the whole PANTS cohort have been reported previously<sup>5</sup>. For this analysis, we selected whole blood samples from a subset of 385 participants treated with infliximab

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

and adalimumab aged >16 years, with a baseline CRP ≥4 mg/L and/or calprotectin >100 µg/g who experienced primary non-response at week 14 and non-remission at week 30 or 54 (n = 99 and 94, respectively), and an equal number of participants as a comparator group who were classified with

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

#### Short title here

primary response at week 14 and subsequent remission (n = 99 and 93, respectively) for DNA methylation profiling. Statistical analyses were undertaken in R 4.1.3 (R Foundation for Statistical Computing, Vienna, Austria). We included patients with missing clinical variables in analyses for which they had the necessary data and have specified the sample size for each variable. Continuous data are reported as median and interguartile range, and discrete data as numbers and percentages. Fisher's exact and Mann-Whitney U tests were used to identify differences in baseline characteristics between infliximab-treated and adalimumab-treated patients. Comparative tests were two-tailed and p value < 0.05 were considered significant unless otherwise stated. DNA methylation was analysed using beta values, the ratio of methylated intensity to the overall intensity at each CpG site, which represents the proportion methylation at each site. Because they influence methylation, a priori, we sought to define DNA methylation changes through the course of the study due to ageing, cigarette smoking and cell composition. Smoking scores were calculated using a weighted sum approach based on previously published smoking-associated methylation probes<sup>32</sup>. Epigenetic age was predicted using 353 CpG sites as described by Horvath<sup>21</sup>. Individual cell proportions of CD4+T cells, CD8+T cells, B cells, granulocytes, and monocytes in each whole blood sample were estimated using the Houseman reference-based algorithm implemented with functions in minfi (v1.32.0)<sup>31</sup> package. Linear mixed effects models, including time on anti-TNF (study visits in weeks) as a fixed effect and modelling individual participants with a random intercept, were used to determine if epigenetic age, smoking behaviour or cell composition were associated with anti-TNF treatment. EWAS analyses of anti-TNF treatment, anti-TNF drug concentration and primary non-response were conducted using linear mixed effects models in this within-subject study, where anti-TNF type and

cell proportions were adjusted for as fixed effects while a random effect (random intercept) was used to capture the individual level effects. Study visits in weeks, reflecting the duration of anti-TNF treatment, was included as an interaction term in the model. Patients treated with infliximab and adalimumab were analysed together to increase the power to detect shared effects. An empirically-derived p value < 9 x 10<sup>-8</sup> was considered significant to control for multiple testing<sup>33</sup>. Pathway analysis with annotations to Gene Ontology (GO) terms was performed using the *gometh* () function in *missMethyl* (v1.28.0)<sup>34</sup> package, which controls for bias arising due to multiple genes being annotated to a single CpG, and multiple CpGs annotated to a single gene. DMPs were searched in the EWAS catalog<sup>35</sup> (http://www.ewascatalog.org/, assessed on 15/12/2022) to look for associations with other common traits. A false discovery rate (FDR) of < 0.05 was considered significant for pathway analysis and associations in the EWAS catalog. We sought overlapping DMPs associated with drug levels and primary non-response and correlation of coefficients was determined using Spearman's test.

#### Ethical and role of the funding source

The sponsor of the study was the Royal Devon and Exeter NHS Foundation Trust. The South West Research Ethics committee approved the study (REC Reference: 12/SW/0323) in January 2013. The funders of this study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Results

#### Short title here

Summary of PANTS DNA methylation dataset DNA methylation was quantified across the genome in 1,104 whole blood DNA samples from 385 individuals across four study visits (baseline, week 14, week 30, week 54) from the PANTS cohort. Following a standard quality control pipeline (see Methods), our final dataset included 784,105 DNA methylation sites quantified in 1,062 samples from 385 participants (Supplementary Figure 1). 87 participants provided samples at all four study visits and the median number of samples per participant was 3 (interquartile range [IQR] 2 – 3) (Supplementary Table 2). Overall, 51.7% (199/385) of participants were female, with a median age of 35.7 years (IQR 26.3 -50.3), 21.2% (81/382) of participants were current smokers and 30.6% (117/382) were former smokers. The median disease duration was 2.2 years [IQR 0.6 - 9.6] and 50.9% (196/385) and 35.3% (136/385) of participants were treated with a concomitant immunomodulator and steroids at baseline, respectively. In total, 51.4% (198/385) of participants were treated with infliximab and 48.6% (187/385) with adalimumab (Table 1). Median infliximab (3.30 mg/L vs 8.09 mg/L, p < 0.001) and adalimumab (7.70 mg/L vs. 13.35 mg/L, p < 0.001) drug concentrations at week 14 were lower in patients who experienced primary non-response, as previously observed in the wider cohort<sup>5</sup>. (Supplementary Figure 2). Anti-TNF treatment is associated with altered blood cell proportions using measures derived from DNA methylation data A number of robust statistical classifiers have been developed to derive estimates of environmental

exposures such as tobacco smoking<sup>32</sup>, biological age<sup>21</sup> and the proportion of different blood cell

types<sup>36</sup> from whole blood DNA methylation data.

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

#### Short title here

As expected, current and former tobacco smokers had a higher DNA methylation-derived smoking score at baseline (former smokers 0.2 [IQR -2.0 - 4.1], p < 0.001 and current smokers 6.6 [IQR 3.3 -9.5], p < 0.001) when compared to never smokers (-2.3 [IQR -3.8 - -1.0]). Over the duration of the study, DNA methylation smoking score increased (effect size per week 0.019, p < 0.001). When compared to current smokers, the trajectory of DNA methylation smoking score changed significantly in former (effect size per week -0.010, p = 0.003), but not current smokers (effect size per week -0.004, p = 0.262) (Supplementary Figure 3) When stratified by response to anti-TNF treatment, following anti-TNF treatment, there was no difference in the trajectory of smoking scores of current smokers (effect size per week - 0.006, p = 0.433) or former smokers (effect size per week -0.0001, p = 0.986) between those who experienced primary non-response compared to those who did not. The epigenetic age of participants measured using the Horvath multi-tissue clock was highly correlated with chronological age of participants at study entry (r = 0.95, p < 0.001). Over the course of the study following anti-TNF treatment, epigenetic age changed with time (effect size per week 0.002, p < 0.001). When stratified by response to anti-TNF treatment, however, there was no difference in the trajectory of change in epigenetic age (effect size per week 0.003, p = 0.71). (Supplementary Figure 4) To understand the immune cell changes following anti-TNF treatment, cell proportion estimates were derived from DNA methylation data. Over time, following anti-TNF treatment, there was a significant increase in the derived proportions of CD4 T cells (effect size per week 0.0013, p < 0.001), CD8 T cells (effect size per week 0.0005, p < 0.001), B cells (effect size per week 0.0004, p < 0.001) and NK cells (effect size per week 0.0001, p = 0.015). (Figure 1) In contrast, the proportion of monocytes (effect size per week -0.0001, p = 0.025) and granulocytes (effect size per week -0.0023, p < 0.001) decreased significantly. In patients who experienced primary non-response, the increase

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

#### Short title here

in proportion of B cells (effect size per week -0.0002, p < 0.001) and CD4 T cells (effect size per week -0.0004, p = 0.048) were less marked over time when compared to those who responded. There was no difference in the change of proportion of granulocytes (effect size per week 0.0002, p = 0.571). Changes in biological processes of the immune pathways occur following anti-TNF treatment Across all patients, 4,999 DMPs (p < 9 x  $10^{-8}$ ) annotated to 2,376 unique genes were associated with anti-TNF treatment (infliximab or adalimumab) regardless of response (Table 2, Figure 2). These DMPs were significantly enriched for sites becoming hypomethylated over time (63.5% [3,176/4,999], p < 0.001). Of treatment-associated DMPs annotated to genes (n = 3,504 [70.1%]), the majority were located in the gene body (67.1% [2,351/3,504]) (Supplementary Figure 5) representing a significant enrichment compared to the background distribution of probes on the EPIC array (67.1% vs 29.5%, p < 0.001). The top-ranked DMP associated with anti-TNF treatment was cg11047325 annotated to the SOCS3 gene, involved in the negative regulation of the JAK-STAT pathway and thought to play a role in modulating the outcome of infections and autoimmune diseases<sup>37</sup> (effect size per week 0.0008, p =  $1.91 \times 10^{-41}$ ). Gene ontology (GO) analysis of genes annotated to treatment-associated DMPs identified 108 significant biological pathways (Supplementary Table 3) further implicating the immune response (immune system process (GO: 0002376, FDR < 0.001), immune response (GO: 0006955, FDR < 0.001), and immune system development (GO:0002520, FDR < 0.001)) alongside pathways related to blood cell differentiation (haematopoietic or lymphoid organ development (GO:0048534, FDR < 0.001) and haemopoiesis (GO: 0030097, FDR < 0.001)) (Supplementary Figure 6).

DNA methylation in infliximab and adalimumab treated patients

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

#### Short title here

Next, we performed an epigenome-wide association study (EWAS) to identify any DMPs associated with anti-TNF treatment type. Overall, there were no significant DMPs at baseline between anti-TNF naïve Crohn's disease patients who were subsequently treated with infliximab or adalimumab. Irrespective of primary non-response status, we observed 13 DMPs annotated to 9 genes with significantly different trajectories following treatment with infliximab compared to adalimumab. The top-ranked DMPs between treatments included cg03446165 [annotated to MMP25] (effect size per week -0.0004, p =  $6.78 \times 10^{-10}$ ), cg12229367 (effect size per week -0.0003, p =  $1.54 \times 10^{-9}$ ) and cg04790662 [annotated to PAG1] (effect size per week -0.0005, p = 2.82 x 10<sup>-9</sup>). (Supplementary Table 4) DNA methylation differences at baseline are associated with anti-TNF drug concentration following treatment We sought to determine if DNA methylation difference at baseline prior to the start of anti-TNF treatment were associated with anti-TNF drug concentrations at week 14. We identified 323 DMPs annotated to 210 genes at baseline associated with anti-TNF drug concentrations at week 14 (Table 3, Figure 3). The top ranked DMP was cg23320029 annotated to the TNIK gene (effect size 0.0555, p. = 4.62 x 10<sup>-15</sup>), encoding the TRAF2 and NCK-interacting kinase, a key regulator in the Wnt signalling pathway implicated in the modulation of immune response during inflammation<sup>38</sup>. GO analysis of genes annotated to DMPs associated with anti-TNF drug concentration at week 14, however, did not identify any FDR (FDR < 0.05) significant pathways. We intersected the list of DMPs predicting anti-TNF drug concentration following treatment with the EWAS catalog<sup>35</sup> to identify overlaps with DNA methylation differences associated with other traits and diseases, finding that 125 (38.7%) DMPs have been previously associated with other common traits (Supplementary Table 5). The most common shared association (proportion of shared CpGs

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

#### Short title here

compared to DMPs) was with an EWAS of body mass index (23.2%), followed by CRP (11.5%), smoking (7.4%), alcohol consumption per day (7.1%) and IBD type (6.8%). The associations with these common traits all had an opposite direction of effect to anti-TNF drug concentration in our cohort; CpG sites associated with a higher BMI and increased CRP were associated with lower anti-TNF drug concentrations, in keeping with the known associations with anti-TNF drug concentration and treatment outcomes<sup>5</sup>. To understand if there was a relationship between anti-TNF drug concentration at week 14 and anti-TNF treatment response, we performed an EWAS of primary non-response to anti-TNF, and identified 48 DMPs annotated to 36 genes at baseline. Of these, 20 DMPs were associated with both anti-TNF drug concentration and primary non-response to anti-TNF (Supplementary Table 6). These DMPs include cg27216853 [CYS1] (effect size to drug concentration -0.0371 vs effect size to primary non-response 0.0245), cg23606775 [CLSTN1] (-0.0220 vs 0.0133) and cg18138532 [UPF2] (-0.0273 vs 0.0157). Overall, there was a strong correlation of the coefficients (Spearman's rho = -0.94, p < 0.001) (Figure 4), suggesting a relationship between DMPs associated with lower anti-TNF drug concentration and primary non-response. Longitudinal changes in DNA methylation differ in patients with primary non-response to anti-TNF treatment Following anti-TNF treatment, intra-individual changes in DNA methylation was significantly different between those who experienced primary non-response to anti-TNF compared to those who did not at 5 DMPs. These sites were cg07839457 [annotated to NLRC5] (effect size per week -0.0007, p =  $1.92 \times 10^{-13}$ ), cg11047325 [annotated to SOCS3] (-0.0007, p =  $3.70 \times 10^{-11}$ ), cg15022400 [annotated to TRIM69] (-0.0003, p = 3.39 x 10<sup>-9</sup>), cg25867318 [annotated to STAT3] (-0.0004, p =  $6.06 \times 10^{-8}$ ) and cg08950751 [annotated to AIP] (-0.0003, p =  $6.82 \times 10^{-8}$ ) (Supplementary Table 7).

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

#### Short title here

The top ranked DMP following anti-TNF treatment cg11047325 annotated to SOCS3 involved in regulation of the JAK-STAT pathway was again identified. Discussion Key results In whole blood, we observed almost 5,000 DMPs annotated to >2,000 genes that are associated with anti-TNF therapy, with the genes annotated to these sites being enriched for biological processes related to immune system processes. 323 DMPs annotated to 210 genes were associated with anti-TNF drug concentration at week 14 and we observed an overlap between differentially methylated probes associated with drug concentrations and primary non-response. Interpretation It is perhaps unsurprising, that treatment with the anti-TNF monoclonal antibodies infliximab and adalimumab led to a significant number of differentially methylated probes across multiple genes that were enriched in immune system pathways. Overall, however, only 13 DMPs were found when comparing infliximab- and adalimumab-treated patients, suggesting that there is an anti-TNF treatment class effect and that both drugs exert a similar effect upon levels of DNA methylation. A similar conclusion was made from a study of patients with rheumatoid arthritis treated with several different anti-TNFs including adalimumab, certolizumab, etanercept, golimumab and infliximab, with no DMPs were identified between different anti-TNF subtypes<sup>39</sup>. The immune cell changes and intracellular signalling pathways in peripheral blood and intestinal tissue following treatment with anti-TNF in patients with IBD is still unclear<sup>40</sup>. Unlike a previous study of 14 patients with IBD<sup>41</sup>, following anti-TNF treatment, we did not observe a change in derived

granulocyte proportions between non-responders and responders, but noted differences in B cells

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

#### Short title here

and CD4 T cells. Derived cell proportions at baseline were, however, not useful as a biomarker of anti-TNF non-response. About a third (38.7%) of the DMPs associated with low drug concentrations were linked to other common traits including body mass index, smoking, and CRP that in the PANTS cohort were associated with drug concentration and anti-TNF treatment failure<sup>5</sup>. It is plausible that these DMPs could be used as blood biomarkers independent of clinical traits to predict inter-individual variability in anti-TNF drug concentration, allowing early effective anti-TNF dose prescribing. Our findings that the DMPs were enriched in gene bodies may suggest a more complex mechanism apart from gene transcription in their role underlying anti-TNF treatment response. The role of gene body methylation is still widely debated, and while they have been associated with the regulation of gene expression, they have a more complex role in suppressing aberrant gene transcription and regulating alternative splicing<sup>42</sup>. With the advancement of single-cell sequencing technologies, the study of specific cell types in both disease specific intestinal tissue<sup>43</sup> and peripheral whole blood<sup>44</sup> perhaps based on our data focussing on the role of B- and CD4<sup>+</sup> T cells, may provide further insights into the molecular mechanisms underlying anti-TNF treatment failure. Whilst there was a strong correlation of effect between DMPs associated with lower drug concentration at week 14 and primary non-response, the modest effect sizes mean that these markers are unlikely to be useful as a diagnostic predictor of primary non-response in individual patients. Why primary non-response is so difficult to predict in patients with IBD is unclear. Few of the so-called precision medicine biomarkers to facilitate the right drug, to the right patient, at the right time have been replicated or translated to clinical care. There are a number of possible reasons for this. Firstly, the challenges of defining primary non-response in the absence of endoscopic outcome data. In the PANTS study, we used a pragmatic composite outcome closely linked to routine clinical care that included patient symptoms assessed using a validated severity scores and

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

#### Short title here

serum CRP. However, there is poor concordance between symptoms and biomarkers and mucosal inflammation. Patients with Crohn's disease may also complain of symptoms suggestive of active disease because of overlapping irritable bowel syndrome, bile acid malabsorption and or small intestinal overgrowth. Further interpretation of potential markers across studies is challenging due to differences in study design, inclusion criteria, improvements in experimental and computational methods over time, and critically confounding by sampling of different tissues and cellular heterogeneity. These challenges may explain why we were unable to replicate here the previous associations with oncostatin M (OSM)<sup>9,10</sup> and triggering receptor expressed on myeloid cells (TREM- $(1)^{11,12}$  identified as potential biomarkers predicting non-response to anti-TNF treatment. Our data argues against the presence of a single epigenetic biomarker in whole blood with clinical utility. Our observations that higher DNA methylation epigenetic smoking score and smoking status, and epigenetic age of participants and chronological age were highly positively correlated internally validates our DNA methylation processing and quality control methods supporting subsequent findings against clinical outcomes. Interestingly, increase in smoking score was observed in all groups regardless of smoking status over time, but was significantly less in former smokers compared to never smokers. Prior longitudinal studies of DNA methylation changes following smoking cessation have reported conflicting results<sup>37,38</sup>, although varying follow-up times and the study of different populations makes it difficult to compare across studies. Whether the DNA methylation changes following smoking cessation have an impact on anti-TNF drug concentration or outcomes in patients with Crohn's disease requires further investigation. Limitations and generalisability We acknowledge some important limitations of our work. First, our outcome data could be

strengthened with endoscopic outcomes. However, we observed a significant association between

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

#### Short title here

clinical outcomes at week 14 and week 54 and faecal calprotectin, which has been shown to closely correlate with endoscopic findings. Second, we measured DNA methylation from whole blood which is likely to be confounded by differences in individual cell proportions. Although we included derived cell proportions as a covariate in our statistical models, this is unlikely to fully control for cellular changes which may be better controlled for by expanded panels of blood cell types or single-cell analyses. Whether similar changes also occur in the target tissues in the small and large intestine is unknown. Third, our findings should be validated in an independent cohort prior to translation into clinical practice. The PANTS study recruited patients from across the UK, and we believe our findings will be generalisable to patients with Crohn's disease treated with an anti-TNF across other western populations. Further work is required to determine if these findings are found in other non-western populations, and indeed in other populations of patients with IBD such as those with ulcerative colitis, and in non-IBD patients treated with an anti-TNF. Conclusion Baseline DNA methylation profiles may be used as a predictor for anti-TNF drug concentration at week 14 to identify patients who may benefit from dose optimisation at the outset of anti-TNF therapy.

# Acknowledgements

S.L. is supported by a Wellcome GW4-CAT fellowship (222850/Z/21/Z). N.C. acknowledges support from Crohn's and Colitis UK. This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. The authors would like to acknowledge James Butler for facilitating this collaboration and Samantha Lent, Justin Wade Davis, Elina Regan, Stephen Abel, Elizabeth Asque and Areej Ammar in the preparation of this manuscript. We also acknowledge John Kirkwood and Anna Barnes from the NIHR Clinical Research Facility for their support with sample preparation, and the study coordinators of the Exeter IBD Research Group, Marian Parkinson and Helen Gardner-Thorpe for their ongoing administrative support to the study.

#### **Funding**

PANTS is an investigator-led study funded by CORE (renamed Guts UK in 2018), the research charity of the British Society of Gastroenterology, and by unrestricted educational grants from AbbVie Inc, USA, Merck Sharp & Dohme Ltd, UK, NAPP Pharmaceuticals Ltd, UK, Pfizer Ltd, USA, Celltrion Healthcare, South Korea, and Cure Crohn's Colitis (Scottish IBD Charity). DNA methylation processing was supported through a sponsored research agreement with AbbVie Inc. The drug and anti-drug antibody assays were provided at reduced cost by Immundiagnostik AG. Laboratory tests were undertaken by the Exeter Blood Sciences Laboratory at the Royal Devon & Exeter National Health Service Trust (https://www.exeterlaboratory.com). The sponsor of the PANTS study is the Royal Devon and Exeter National Health Service Foundation Trust. None of the listed funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and decision to submit the manuscript for publication.

**Conflict of Interest** 

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

Simeng Lin reports non-financial support from Pfizer outside the submitted work. Mark Reppell, Jeffrey F Waring, Valerie Pivorunas, Nizar Smaoui, Heath Guay are employees of AbbVie and may own stock/options. Nicholas A. Kennedy reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik; grants and non-financial support from AbbVie, grants and personal fees from Celltrion, personal fees and non-financial support from Janssen, personal fees from Takeda, and personal fees and non-financial support from Dr Falk, outside the submitted work. James R. Goodhand reports grants from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik outside the conduct of the study. Tariq Ahmad reports grants and non-financial support from F. Hoffmann-La Roche AG, grants from Biogen Inc, grants from Celltrion Healthcare, grants from Galapagos NV and non-financial support from Immundiagnostik; personal fees from Biogen inc, grants and personal fees from Celltrion Healthcare, personal fees and non-financial support from Immundiagnostik, personal fees from Takeda, personal fees from ARENA, personal fees from Gilead, personal fees from Adcock Ingram Healthcare, personal fees from Pfizer, personal fees from Genentech and non-financial support from Tillotts, outside the submitted work. Eilis Hannon, Claire Bewshea, Neil Chanchlani and Jonathan Mill declare no competing interests.

### **Author Contributions**

NAK, JRG, TA participated in the conception and design of this study. CB was the project manager and coordinated patient recruitment. SL, EH, NS, JFW, VP, HG, CB, NC, BB, NAK, JRG, JM, TA were involved in the acquisition, analysis or interpretation of data. Data analysis was done by SL and EH. Drafting of the manuscript was done by SL, EH, NS, JFW, VP, HG, NC, BB, NAK, JRG, JM, TA. TA

obtained the funding for the study. All the authors contributed to the critical review and final approval of the manuscript. JM and TA have verified the underlying data.

Data availability statement

Individual participant de-identified data that underlie the results reported in this article will be available immediately after publication for a period of 5 years. The data will be made available to investigators whose proposed use of the data has been approved by an independent review committee. Analyses will be restricted to the aims in the approved proposal. Proposals should be directed to tariq.ahmad1@nhs.net. To gain access data requestors will need to sign a data access agreement.

References

448

449 Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy 1. 450 and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review 451 and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Dec 1;6(12):1002-14. 452 2. Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in 453 induction and maintenance of remission in luminal Crohn's disease: systematic review and 454 network meta-analysis. Gut [Internet]. 2022 Jul 30 [cited 2022 Sep 8];0:gutjnl-2022-328052. 455 Available from: https://gut.bmj.com/content/early/2022/07/29/gutjnl-2022-328052 456 3. Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review 457 with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing 458 hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 459 [Internet]. 2017 Jan 1 [cited 2022 Sep 9];45(1):3–13. Available from: 460 https://pubmed.ncbi.nlm.nih.gov/27862107/ 461 4. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, et al. Role for 462 therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution 463 in the definition and management of primary nonresponse. Inflamm Bowel Dis [Internet]. 464 2015 Jan;21(1):182-97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25222660 465 5. Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, et al. Predictors of anti-466 TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a 467 prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;1253(19):1-13. 468 6. Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, et al. HLA-DQA1\*05 469 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and 470 Adalimumab in Patients With Crohn's Disease. Gastroenterology [Internet]. 2020;158(1):189– 471 99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31600487

472 7. Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-Driven 473 Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces 474 Immunogenicity. Inflamm Bowel Dis [Internet]. 2022 Sep 1 [cited 2022 Dec 20];28(9):1375-475 85. Available from: https://pubmed.ncbi.nlm.nih.gov/34978325/ 476 8. Lawrence S, Faytrouni F, Harris RE, Irvine M, Carrion E, Scott G, et al. Optimized Infliximab 477 Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard 478 Induction Dosing, J Pediatr Gastroenterol Nutr [Internet]. 2022 Nov 1 [cited 2022 Dec 20];75(5):601-7. Available from: https://pubmed.ncbi.nlm.nih.gov/36048178/ 479 480 9. West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives 481 intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy 482 in patients with inflammatory bowel disease. Nat Med [Internet]. 2017 [cited 2022 Sep. 483 9];23(5):579-89. Available from: https://pubmed.ncbi.nlm.nih.gov/28368383/ 484 10. Verstockt S, Verstockt B, MacHiels K, Vancamelbeke M, Ferrante M, Cleynen I, et al. 485 Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic 486 Nonresponse in Inflammatory Bowel Disease. Inflamm Bowel Dis [Internet]. 2021 Oct 1 [cited 487 2022 Sep 9];27(10):1564-75. Available from: https://pubmed.ncbi.nlm.nih.gov/33624092/ 488 11. Gaujoux R, Starosvetsky E, Maimon N, Vallania F, Bar-Yoseph H, Pressman S, et al. Cell-489 centred meta-analysis reveals baseline predictors of anti-TNFlpha non-response in biopsy and 490 blood of patients with IBD. Gut [Internet]. 2019 Apr 1 [cited 2022 Sep 9];68(4):604-14. 491 Available from: https://gut.bmj.com/content/68/4/604 492 12. Verstockt B, Verstockt S, Dehairs J, Ballet V, Blevi H, Wollants WJ, et al. Low TREM1 493 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. 494 EBioMedicine [Internet]. 2019 Feb 1 [cited 2022 Sep 9];40:733. Available from: 495 /pmc/articles/PMC6413341/

496 13. Sudhakar P, Alsoud D, Wellens J, Verstockt S, Arnauts K, Verstockt B, et al. Tailoring Multi-497 omics to Inflammatory Bowel Diseases: All for One and One for All. J Crohn's Colitis [Internet]. 498 2022 Aug 30 [cited 2022 Dec 20];16(8):1306-20. Available from: 499 https://academic.oup.com/ecco-jcc/article/16/8/1306/6527686 500 14. Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC, et al. Results of the 501 Seventh Scientific Workshop of ECCO: Precision Medicine in IBD—Disease Outcome and 502 Response to Therapy. J Crohn's Colitis [Internet]. 2021 Sep 25 [cited 2022 Dec 503 19];15(9):1431-42. Available from: https://academic.oup.com/ecco-504 jcc/article/15/9/1431/6175314 505 15. Dor Y, Cedar H. Principles of DNA methylation and their implications for biology and 506 medicine. Lancet. 2018 Sep 1;392(10149):777-86. 507 16. Schübeler D. Function and information content of DNA methylation. Nat 2015 5177534 508 [Internet]. 2015 Jan 14 [cited 2023 Feb 1];517(7534):321-6. Available from: 509 https://www.nature.com/articles/nature14192 510 Wan J, Oliver VF, Wang G, Zhu H, Zack DJ, Merbs SL, et al. Characterization of tissue-specific 17. 511 differential DNA methylation suggests distinct modes of positive and negative gene 512 expression regulation. BMC Genomics [Internet]. 2015 Feb 5 [cited 2023 Feb 1];16(1):1-11. 513 Available from: https://bmcgenomics.biomedcentral.com/articles/10.1186/s12864-015-514 1271-4 515 18. de Mendoza A, Nguyen TV, Ford E, Poppe D, Buckberry S, Pflueger J, et al. Large-scale 516 manipulation of promoter DNA methylation reveals context-specific transcriptional responses 517 and stability. Genome Biol [Internet]. 2022 Dec 1 [cited 2023 Feb 1];23(1):1-31. Available 518 from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-022-02728-5 519 19. Villicaña S, Bell JT. Genetic impacts on DNA methylation: research findings and future

520 perspectives. Genome Biol 2021 221 [Internet]. 2021 Apr 30 [cited 2023 Feb 1];22(1):1–35. 521 Available from: https://genomebiology.biomedcentral.com/articles/10.1186/s13059-021-02347-6 522 523 20. Hannon E, Knox O, Sugden K, Burrage J, Wong CCY, Belsky DW, et al. Characterizing genetic 524 and environmental influences on variable DNA methylation using monozygotic and dizygotic 525 twins. PLOS Genet [Internet]. 2018 Aug 1 [cited 2022 Sep 9];14(8):e1007544. Available from: 526 https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1007544 527 21. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol [Internet]. 528 2013 Oct 21 [cited 2022 Sep 8];14(10):1–20. Available from: 529 https://genomebiology.biomedcentral.com/articles/10.1186/gb-2013-14-10-r115 530 22. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: Impact on disease 531 course and insights into the aetiology of its effect. J Crohn's Colitis [Internet]. 2014 Aug 1 532 [cited 2022 Sep 30];8(8):717–25. Available from: https://academic.oup.com/ecco-533 jcc/article/8/8/717/530121 534 23. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-Wide Association Studies for common 535 human diseases. Nat Rev Genet [Internet]. 2011 Aug [cited 2023 Feb 1];12(8):529. Available 536 from: /pmc/articles/PMC3508712/ 537 24. Birney E, Smith GD, Greally JM. Epigenome-wide Association Studies and the Interpretation of 538 Disease -Omics. PLOS Genet [Internet]. 2016 Jun 1 [cited 2023 Feb 1];12(6):e1006105. 539 Available from: 540 https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1006105 541 25. McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, Keegan D, et al. DNA Methylation 542 Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis. J 543 Crohns Colitis [Internet]. 2016 Jan 1 [cited 2022 Sep 8];10(1):77-86. Available from:

544 https://pubmed.ncbi.nlm.nih.gov/26419460/ 545 26. Somineni HK, Venkateswaran S, Kilaru V, Marigorta UM, Mo A, Okou DT, et al. Blood-Derived 546 DNA Methylation Signatures of Crohn's Disease and Severity of Intestinal Inflammation. 547 Gastroenterology [Internet]. 2019 Jun 1 [cited 2022 Sep 8];156(8):2254-2265.e3. Available 548 from: https://pubmed.ncbi.nlm.nih.gov/30779925/ 549 27. Fisel P, Schaeffeler E, Schwab M. DNA Methylation of ADME Genes. Clin Pharmacol Ther 550 [Internet]. 2016 May 1 [cited 2022 Dec 20];99(5):512–27. Available from: 551 https://onlinelibrary.wiley.com/doi/full/10.1002/cpt.343 552 28. Nair N, Plant D, Plant D, Verstappen SM, Verstappen SM, Isaacs JD, et al. Differential DNA 553 methylation correlates with response to methotrexate in rheumatoid arthritis. Rheumatology 554 (Oxford) [Internet]. 2020 Jun 1 [cited 2022 Sep 9];59(6):1364–71. Available from: 555 https://pubmed.ncbi.nlm.nih.gov/31598719/ 556 29. Plant D, Webster A, Nair N, Oliver J, Smith SL, Eyre S, et al. Differential Methylation as a 557 Biomarker of Response to Etanercept in Patients with Rheumatoid Arthritis. Arthritis 558 Rheumatol [Internet]. 2016 Jun 1 [cited 2022 Sep 9];68(6):1353-60. Available from: 559 https://onlinelibrary.wiley.com/doi/full/10.1002/art.39590 560 30. Gorrie-Stone TJ, Smart MC, Saffari A, Malki K, Hannon E, Burrage J, et al. Bigmelon: tools for 561 analysing large DNA methylation datasets. Bioinformatics [Internet]. 2019 Mar 15 [cited 2022 562 Sep 8];35(6):981-6. Available from: 563 https://academic.oup.com/bioinformatics/article/35/6/981/5078475 564 31. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a 565 flexible and comprehensive Bioconductor package for the analysis of Infinium DNA 566 methylation microarrays. Bioinformatics [Internet]. 2014 May 15 [cited 2022 Sep 567 8];30(10):1363-9. Available from: https://pubmed.ncbi.nlm.nih.gov/24478339/

568 32. Elliott HR, Tillin T, McArdle WL, Ho K, Duggirala A, Frayling TM, et al. Differences in smoking 569 associated DNA methylation patterns in South Asians and Europeans. Clin Epigenetics 570 [Internet]. 2014 Feb 3 [cited 2022 Sep 8];6(1):1–10. Available from: 571 https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/1868-7083-6-4 572 33. Mansell G, Gorrie-Stone TJ, Bao Y, Kumari M, Schalkwyk LS, Mill J, et al. Guidance for DNA 573 methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics 574 [Internet]. 2019 May 14 [cited 2022 Sep 8];20(1). Available from: 575 /pmc/articles/PMC6518823/ 576 34. Phipson B, Maksimovic J, Oshlack A. missMethyl: an R package for analyzing data from 577 Illumina's HumanMethylation450 platform. Bioinformatics [Internet]. 2016 Jan 15 [cited 2022 578 Sep 8];32(2):286-8. Available from: 579 https://academic.oup.com/bioinformatics/article/32/2/286/1744111 580 35. Battram T, Yousefi P, Crawford G, Prince C, Sheikhali Babaei M, Sharp G, et al. The EWAS 581 Catalog: a database of epigenome-wide association studies. Wellcome Open Res 2022 741 582 [Internet]. 2022 May 31 [cited 2022 Sep 8];7:41. Available from: 583 https://wellcomeopenresearch.org/articles/7-41 584 36. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA 585 methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 586 [Internet]. 2012 May 8 [cited 2023 Feb 1];13(1):1–16. Available from: 587 https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2105-13-86 588 37. Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front 589 Immunol. 2014 Feb 19;5(FEB):58. 590 38. Jridi I, Canté-Barrett K, Pike-Overzet K, Staal FJT. Inflammation and Wnt Signaling: Target for 591 Immunomodulatory Therapy? Front Cell Dev Biol. 2021 Feb 4;8:1854.

592 39. Julià A, Gómez A, López-Lasanta M, Blanco F, Erra A, Fernández-Nebro A, et al. Longitudinal 593 analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis 594 factor inhibitor therapy in rheumatoid arthritis. eBioMedicine [Internet]. 2022 Jun 1 [cited 595 2022 Sep 30];80. Available from: 596 http://www.thelancet.com/article/S2352396422002341/fulltext 597 40. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of Action of Anti-TNF Therapy in 598 Inflammatory Bowel Disease. J Crohn's Colitis [Internet]. 2016 Aug 1 [cited 2022 Dec 599 22];10(8):989-97. Available from: https://academic.oup.com/ecco-600 jcc/article/10/8/989/2392174 601 Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, et al. Longitudinal multi-omics analysis 41. 602 identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel 603 disease. Genome Med [Internet]. 2022 Dec 1 [cited 2022 Dec 22];14(1):1–20. Available from: 604 https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01112-z 605 42. Wang Q, Xiong F, Wu G, Liu W, Chen J, Wang B, et al. Gene body methylation in cancer: molecular mechanisms and clinical applications. Clin Epigenetics 2022 141 [Internet]. 2022 606 607 Nov 28 [cited 2022 Dec 23];14(1):1–14. Available from: 608 https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-022-01382-9 609 43. Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, et al. Single-Cell Analysis of 610 Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to 611 Anti-TNF Therapy. Cell [Internet]. 2019 Sep 5 [cited 2022 Dec 22];178(6):1493-1508.e20. 612 Available from: http://www.cell.com/article/S0092867419308967/fulltext 613 44. Peres RS, Thomas T, Friedrich M, Pohin M, Pearson C, Ferreira RC, et al. Anti-TNF-induced IL-614 27 modulates regulatory T cell responses in patients with IBD that respond to therapy. 615 bioRxiv [Internet]. 2022 Nov 21 [cited 2022 Dec 22];2022.11.21.517257. Available from:

https://www.biorxiv.org/content/10.1101/2022.11.21.517257v1

616

617

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

#### Short title here

Figure Legends Figure 1: Change in derived cell proportions following treatment with anti-TNF. Predicted derived cell proportions over time estimated from the regression analysis is represented in solid blue lines, and observed cell proportions in faded lines. P value represents the change in individual cell proportions over time. Figure 2: Manhattan plot of CpG sites associated with change over time following anti-TNF drug exposure regardless of treatment outcome. The top 10 differentially methylated probes with annotations are labelled in the plot. The grey horizontal line represents the significant p value threshold of 9 x 10<sup>-8</sup>. Figure 3: Manhattan plot of CpG sites at baseline associated with anti-TNF drug concentration at week 14. The top 10 CpG sites with their associated gene annotations are labelled in brackets. The grey horizontal line represents the significant p value threshold of  $9 \times 10^8$ . Figure 4: Coefficients of DMPs associated with anti-TNF drug concentration at week 14 and primary non-response. Coefficients represent the beta values of each CpG from linear mixed effects model to each outcome. Spearman's rho correlation of the coefficients calculated for those that were associated with both anti-TNF drug concentration and primary non-response, and the remaining that were only significant to anti-TNF drug concentration. Abbreviations: PNR = primary non-response.

Variable	Level adalimumab infliximab			Overall	р	
n		187	198	385		
Age at first dose		37.19 (26.56 - 51.15)	35.25 (25.57 - 49.49)	35.69 (26.34 - 50.26)	0.466	
Sex	Female	47.06% (88/187)	56.06% (111/198)	51.69% (199/385)	0.083	
	Male	52.94% (99/187)	43.94% (87/198)	48.31% (186/385)		
Ethnicity	White	94.12% (176/187)	94.95% (188/198)	94.55% (364/385)	0.933	
	South Asian	2.14% (4/187)	2.02% (4/198)	2.08% (8/385)		
	Other	3.74% (7/187)	3.03% (6/198)	3.38% (13/385)		
Smoking history	Current	17.20% (32/186)	25.00% (49/196)	21.20% (81/382)	0.163	
	Ex	33.33% (62/186)	28.06% (55/196)	30.63% (117/382)		
	Never	49.46% (92/186)	46.94% (92/196)	48.17% (184/382)		
Disease duration	Disease duration		2.08 (0.53 - 9.52)	2.17 (0.56 - 9.53)	0.483	
Montreal location	L1	31.52% (58/184)	29.44% (58/197)	30.45% (116/381)	0.956	
classification	L2	25.54% (47/184)	26.90% (53/197)	26.25% (100/381)		
	L3	42.39% (78/184)	43.15% (85/197)	42.78% (163/381)		
	L4	0.54% (1/184)	0.51% (1/197)	0.52% (2/381)		
Montreal	B1	59.24% (109/184)	63.96% (126/197)	61.68% (235/381)	0.035	
behaviour	B2	35.33% (65/184)	25.38% (50/197)	30.18% (115/381)		
classification	В3	5.43% (10/184)	10.66% (21/197)	8.14% (31/381)		
Immunomodulator use at baseline	TRUE	52.94% (99/187)	48.99% (97/198)	50.91% (196/385)	0.476	
Steroid use at baseline	TRUE	29.41% (55/187)	40.91% (81/198)	35.32% (136/385)	0.019	
C-reactive protein (n	C-reactive protein (mg/L)		12.00 (5.00 - 32.00)	10.00 (5.00 - 24.00)	0.013	
HBI score		5.00 (3.00 - 8.00)	6.00 (3.00 - 9.50)	5.00 (3.00 - 9.00)	0.256	
Faecal calprotectin (ug/g)		307.00 (159.50 - 599.00)	481.00 (251.00 - 365.00 (188.00 - 726.00)		0.001	
Haemoglobin (g/L)		129.50 (120.00 - 140.00)	125.00 (112.00 - 128.00 (116.00 135.00) 137.00)		0.002	
White cell count (x 10 <sup>9</sup> cells per L)		7.90 (6.20 - 10.20)	8.56 (6.60 - 10.70)	8.23 (6.40 - 10.40)	0.166	

Table 1: Characteristics at baseline of participants stratified by type of anti-TNF

639 640

CpG	chr	pos	Relation	Gene name	Gene group	Coefficient (per	P value
			to Island			week)	
cg11047325	17	76354934	Island	SOCS3	Body	0.0008	1.91E-41
cg17501210	6	166970252	OpenSea	RPS6KA2	Body	0.0007	1.40E-38
cg19748455	17	76274856	OpenSea	LOC100996291	TSS1500	0.0008	2.55E-37
cg00840791	19	16453259	OpenSea			0.0011	1.02E-35
cg12992827	3	101901234	OpenSea			0.0010	2.23E-33
cg04051206	17	17750855	OpenSea	TOM1L2	3'UTR	0.0005	4.19E-31
cg03546163	6	35654363	N_Shore	FKBP5	5'UTR	0.0012	4.87E-31
cg01526748	3	191930926	OpenSea	FGF12	Body	-0.0005	1.97E-30
cg13074526	17	76274743	OpenSea	LOC100996291	TSS200	0.0008	2.32E-30
cg18608055	19	1130866	OpenSea	SBNO2	Body	0.0008	4.57E-30

Table 2: Top 10 differentially methylated probes associated with anti-TNF treatment over time

			Relation	Gene	Gene	Coefficient (per	
CpG	chr	pos	to Island	name	group	week)	P value
cg23320029	3	171004750	OpenSea	TNIK	Body	0.0555	4.62E-15
cg16500036	7	68983906	OpenSea			-0.0409	1.61E-14
cg18513344	3	195531298	OpenSea	MUC4	Body	0.0299	4.90E-14
cg21635197	6	135405808	OpenSea			0.0389	8.71E-13
cg22870160	1	231830793	OpenSea	DISC1	Body	-0.0376	1.23E-12
cg03403209	16	29666641	OpenSea			-0.0247	1.51E-12
cg07856599	1	227151843	OpenSea	ADCK3	Body	-0.0411	6.82E-12
cg01950011	8	37396511	OpenSea			-0.0213	8.00E-12
cg27216853	2	10205672	OpenSea	CYS1	Body	-0.0371	8.79E-12
cg02011576	3	38060265	OpenSea	PLCD1	Body	-0.0387	8.82E-12

Table 3: Top 10 differentially methylated probes at baseline associated with anti-TNF drug concentration at week 14

644 645




Figure 1: Change in derived cell proportions following treatment with anti-TNF. Predicted derived cell proportions over time estimated from the regression analysis is represented in solid blue lines, and observed cell proportions in faded lines. P value represents the change in individual cell proportions over time.




Figure 2: Manhattan plot of CpG sites associated with change over time following anti-TNF drug exposure regardless of treatment outcome. The top 10 differentially methylated probes with annotations are labelled in the plot. The grey horizontal line represents the significant p value threshold of  $9 \times 10^{-8}$ .




Figure 3: Manhattan plot of CpG sites at baseline associated with anti-TNF drug concentration at week 14. The top 10 CpG sites with their associated gene annotations are labelled in brackets. The grey horizontal line represents the significant p value threshold of  $9 \times 10^{-8}$ .




Figure 4: Coefficients of DMPs associated with anti-TNF drug concentration at week 14 and primary non-response. Coefficients represent the beta values of each CpG from linear mixed effects model to each outcome. Spearman's rho correlation of the coefficients calculated for those that were associated with both anti-TNF drug concentration and primary non-response, and the remaining that were only significant to anti-TNF drug concentration. Abbreviations: PNR = primary non-response.